Beta 2 microglobulin, serum

Alphabetical Test listing

Beta 2 microglobulin, serum-1096

  
Beta 2 microglobulin, serum
  
1096
  
82232.2
  
B2M
  
β-2 microglobulin, serum
Beta-2-microglobulin
B2M
B2-M
B-2
B-2 Microglobulin
B2 Microglobulin
Beta 2 microglobulin
  

Beta-2-Microglobulin (B2M) is used to evaluate the prognosis of patients with multiple myeloma.

  
Serum
  
  
1.0 mL
  
0.5 mL
  

Spin

  

Gold serum separator (SST) tube

  
  
  1. Spin
  2. Transferserum to a False bottom plasma/serum transport vial/tube (AHL)

 

  
  

Refrigerated (preferred) - 7 days
Frozen (OK)

  
  • Improper labels (unlabeled or mislabeled)
  • Hemolysis (some procedures)
  • Improper anticoagulant or ratio
  • Delay in transport
  • Improper storage temperature affecting results
  • Improper container
  • Leaking container resulting in compromised specimen
  • Quantity not sufficient (QNS)
  
AHL - Immunology: I
  
Tu, Fr
  
3 - 4 days
  

Turbidimetric

  

0.8 - 2.34 µg/mL

  

Serum levels are elevated in diseases associated with increased cell turnover. In multiple myeloma, B2M is a powerful prognostic factor and values <4 ìg/mL are considered a good prognostic indicator. Studies have shown that the median survival of patients with B2M values >4 ìg/mL was approximately 1 year, whereas median survival for patients with B2M values <4 ìg/mL was approximately 3.75 years.

Beta-2-Microglobulin is also elevated in chronic inflammation, liver disease, renal dysfunction, some acute viral infections, and a number of malignancies, especially hematologic disorders associated with the B-lymphocytes.

In renal tubular disease, serum B2M levels are low and urine levels are high.

  
82232
  
07/30/2007
  
04/06/2021
  
02/17/2020